Cynthia Lynne Collins's Insider Trades & SAST Disclosures
Cynthia Lynne Collins's most recent trade in Codexis Inc. was a trade of 71,174 Common Stock done . Disclosure was reported to the exchange on March 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Cynthia Lynne Collins.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Codexis Inc. | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 71,174 | 71,174 (0%) | 0% | 0 | Common Stock | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 87,440 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | 08 Jan 2025 | 58,950 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 28,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2024 | 97,698 | 97,698 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2024 | 51,679 | 51,679 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges